A randomized, double-blinded, international phase III trial comparing HLX22 in combination with trastuzumab and chemotherapy versus trastuzumab and chemotherapy with or without pembrolizumab for first-line treatment for HER2-positive locally advanced or metastatic G/GEJ cancer. - KIVIRID

A randomized, double-blinded, international phase III trial comparing HLX22 in combination with trastuzumab and chemotherapy versus trastuzumab and chemotherapy with or without pembrolizumab for first-line treatment for HER2-positive locally advanced or metastatic G/GEJ cancer.

Authors: Jaffer A. Ajani, Ken Kato, Futang Yang, Qingyu Wang, Lin Shen

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps4206

Source: Full article

Abstract

TPS4206